Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 06/01/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Tekla Life Sciences Investors of Benef Interest

HQL | Fund

$19.54

$587 M

11.46%

$2.24

1.24%

Vitals

YTD Return

11.8%

1 yr return

59.6%

3 Yr Avg Return

19.4%

5 Yr Avg Return

9.7%

Net Assets

$587 M

Holdings in Top 10

50.6%

52 WEEK LOW AND HIGH

$19.9
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 1.24%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 62.37%

Redemption Fee N/A

Min Investment

Standard (Taxable)

N/A

IRA

N/A

Fund Classification

Fund Type

Closed-end mutual fund

Name

As of 06/01/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Tekla Life Sciences Investors of Benef Interest

HQL | Fund

$19.54

$587 M

11.46%

$2.24

1.24%

HQL - Profile

Distributions

  • YTD Total Return 11.8%
  • 3 Yr Annualized Total Return 19.4%
  • 5 Yr Annualized Total Return 9.7%
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.80%
DIVIDENDS
  • Dividend Yield 11.5%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    Tekla Life Sciences Investors of Benef Interest
  • Fund Family Name
    Tekla Capital Management LLC
  • Inception Date
    Nov 22, 2011
  • Shares Outstanding
    25144038
  • Share Class
    Other
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Daniel Omstead

Fund Description

HQL - Performance

Return Ranking - Trailing

Period HQL Return Category Return Low Category Return High Rank in Category (%)
YTD 11.8% -22.9% 20.0% 2.50%
1 Yr 59.6% -20.4% 134.5% 8.13%
3 Yr 19.4%* -6.3% 23.9% 3.75%
5 Yr 9.7%* -15.5% 12.3% 5.16%
10 Yr 9.3%* 3.0% 13.1% 28.35%

* Annualized

Return Ranking - Calendar

Period HQL Return Category Return Low Category Return High Rank in Category (%)
2025 23.7% -21.9% 61.0% 18.13%
2024 -7.4% -28.2% 19.2% 86.88%
2023 -2.2% -8.6% 19.0% 81.25%
2022 -15.6% -53.9% 3.2% 76.13%
2021 -9.3% -39.6% 24.2% 72.90%

Total Return Ranking - Trailing

Period HQL Return Category Return Low Category Return High Rank in Category (%)
YTD 11.8% -22.9% 20.0% 2.50%
1 Yr 59.6% -20.4% 134.5% 8.13%
3 Yr 19.4%* -6.3% 23.9% 3.75%
5 Yr 9.7%* -15.5% 12.3% 5.16%
10 Yr 9.3%* 3.0% 13.1% 28.35%

* Annualized

Total Return Ranking - Calendar

Period HQL Return Category Return Low Category Return High Rank in Category (%)
2025 38.7% -0.5% 63.7% 9.38%
2024 4.0% -28.2% 19.2% 31.88%
2023 6.1% -8.6% 19.0% 31.25%
2022 -8.4% -53.9% 3.7% 40.65%
2021 -1.7% -33.9% 26.0% 81.94%

NAV & Total Return History

HQL - Holdings

Concentration Analysis

HQL Category Low Category High HQL % Rank
Net Assets 587 M 6.38 M 37.9 B 57.50%
Number of Holdings 145 24 416 16.25%
Net Assets in Top 10 247 M 3.49 M 22.8 B 58.75%
Weighting of Top 10 50.56% 16.2% 79.4% 26.25%

Top 10 Holdings

  1. Moderna Inc 7.94%
  2. Gilead Sciences Inc 7.64%
  3. Amgen Inc 6.91%
  4. Regeneron Pharmaceuticals Inc 5.61%
  5. Illumina Inc 5.02%
  6. Horizon Therapeutics PLC 4.83%
  7. Seagen Inc Ordinary Shares 4.64%
  8. Vertex Pharmaceuticals Inc 4.30%
  9. Alexion Pharmaceuticals Inc 4.15%
  10. Biogen Inc 4.00%

Asset Allocation

Weighting Return Low Return High HQL % Rank
Stocks 		91.87% 88.27% 106.13% 91.25%
Preferred Stocks 		7.86% 0.00% 7.86% 0.63%
Cash 		2.51% 0.00% 32.31% 41.88%
Convertible Bonds 		0.00% 0.00% 0.37% 12.90%
Bonds 		0.00% 0.00% 12.39% 20.63%
Other 		-2.25% -22.99% 4.13% 96.88%

Stock Sector Breakdown

Weighting Return Low Return High HQL % Rank
Healthcare 		99.82% 59.26% 100.00% 54.19%
Financial Services 		0.18% 0.00% 1.60% 16.13%
Utilities 		0.00% 0.00% 0.00% 5.81%
Technology 		0.00% 0.00% 22.69% 11.61%
Real Estate 		0.00% 0.00% 5.89% 10.97%
Industrials 		0.00% 0.00% 7.02% 11.61%
Energy 		0.00% 0.00% 0.00% 5.81%
Communication Services 		0.00% 0.00% 9.11% 9.03%
Consumer Defense 		0.00% 0.00% 25.73% 14.84%
Consumer Cyclical 		0.00% 0.00% 1.92% 11.61%
Basic Materials 		0.00% 0.00% 7.16% 37.42%

Stock Geographic Breakdown

Weighting Return Low Return High HQL % Rank
US 		83.97% 60.50% 104.41% 71.88%
Non US 		7.90% 0.00% 36.86% 24.38%

HQL - Expenses

Operational Fees

HQL Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.24% 0.08% 4.69% 43.13%
Management Fee 0.98% 0.03% 1.25% 86.25%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

HQL Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

HQL Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

HQL Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 62.37% 1.00% 238.00% 76.81%

HQL - Distributions

Dividend Yield Analysis

HQL Category Low Category High HQL % Rank
Dividend Yield 11.46% 0.00% 6.24% 38.75%

Dividend Distribution Analysis

HQL Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annual Annual Annual

Net Income Ratio Analysis

HQL Category Low Category High HQL % Rank
Net Income Ratio -0.80% -2.54% 1.85% 83.01%

Capital Gain Distribution Analysis

HQL Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Distributions History

View More +

HQL - Fund Manager Analysis

Managers

Daniel Omstead

Start Date

Tenure

Tenure Rank

Sep 30, 2001

20.68

20.7%

Omstead is president and chief executive officer of Tekla Capital Management, formerly known as Hambrecht & Quist Capital Management, Inc. Before joining the adviser, Omstead was president and CEO of Reprogenesis, Inc., a private development stage biotech company developing therapies in the field of regenerative medicine. Before joining Reprogenesis, he was senior vice president, research and development at Cytotherapeutics, Inc., a public biotech company that developed CNS therapies.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 8.08 0.25

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.